Etofibrate
CAS No. 31637-97-5
Etofibrate( Nicotinic Acid )
Catalog No. M14031 CAS No. 31637-97-5
Etofibrate is a combination of clofibrate and niacin, used to treat hyperlipemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 36 | In Stock |
|
| 25MG | 59 | In Stock |
|
| 50MG | 77 | In Stock |
|
| 100MG | 117 | In Stock |
|
| 200MG | 178 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEtofibrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionEtofibrate is a combination of clofibrate and niacin, used to treat hyperlipemia.
-
DescriptionEtofibrate is a combination of clofibrate and niacin, used to treat hyperlipemia.(In Vivo):Etofibrate is the ethandiol-1,2 diester of the nicotinic and clofibric acids. Etofibrate has been shown to be a potent hypolipidemic agent in animal and human. After 10 days of treatment with Etofibrate, the rats show a body weight similar to that found in the control animals but their liver weight is significantly enhanced whereas plasma cholesterol and triacylglycerol levels are decreased. Etofibrate treatment increases the bile flow of the animals, the effect being especially manifest during the first 2 hr after interruption of the enterohepatic circulation and the difference with the controls becomes statistically significant at 30 and 90 min. The cumulative amount of bile secreted plotted against time shows a highly significant linear correlation for both control and Etofibrate treated rats, the slope being significantly higher for the Etofibrate group than for controls.
-
In Vitro——
-
In VivoEtofibrate is the ethandiol-1,2 diester of the nicotinic and clofibric acids. Etofibrate has been shown to be a potent hypolipidemic agent in animal and human. After 10 days of treatment with Etofibrate, the rats show a body weight similar to that found in the control animals but their liver weight is significantly enhanced whereas plasma cholesterol and triacylglycerol levels are decreased. Etofibrate treatment increases the bile flow of the animals, the effect being especially manifest during the first 2 hr after interruption of the enterohepatic circulation and the difference with the controls becomes statistically significant at 30 and 90 min. The cumulative amount of bile secreted plotted against time shows a highly significant linear correlation for both control and Etofibrate treated rats, the slope being significantly higher for the Etofibrate group than for controls.
-
SynonymsNicotinic Acid
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number31637-97-5
-
Formula Weight363.79
-
Molecular FormulaC18H18ClNO5
-
Purity>98% (HPLC)
-
SolubilityEthanol: 73 mg/mL (200.66 mM); DMSO: 73 mg/mL (200.66 mM)
-
SMILESO=C(C1=CC=CN=C1)OCCOC(C(C)(OC2=CC=C(Cl)C=C2)C)=O
-
Chemical Name2-[2-(4-Chlorophenoxy)-2-methylpropanoyl]oxyethyl pyridine-3-carboxylate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Herrera E, et al. Biochim Biophys Acta, 1988, 963(1), 42-52.
molnova catalog
related products
-
Trachelogenin
Trachelogenin, an HCV entry inhibitor, has antiproliferative effects, and its mechanism is related to affecting the phosphorylation of key proteins in the β-Catenin signaling pathway, such as β-Catenin, c-Myc, and GSK3, in a concentration-dependent manner.
-
Tiaramide hydrochlor...
Tiaramide hydrochloride is an anti-inflammatory drug that inhibits the action of mediators released from mast cells and has direct smooth muscle relaxant properties.
-
C3a (70-77) TFA (635...
C3a (70-77) TFA (Complement 3a (70-77) TFA) is a COOH-terminal fragment of the C3a anaphylatoxin peptide.
Cart
sales@molnova.com